Skip to content

Pembrolizumab

Keytruda (pembrolizumab) is an antibody pharmaceutical. Pembrolizumab was first approved as Keytruda on 2014-09-04. It is used to treat hodgkin disease, melanoma, microsatellite instability, non-small-cell lung carcinoma, and squamous cell carcinoma amongst others in the USA. It has been approved in Europe to treat hodgkin disease, melanoma, non-small-cell lung carcinoma, renal cell carcinoma, and squamous cell carcinoma of head and neck amongst others. The pharmaceutical is active against programmed cell death protein 1.
Trade Name Keytruda
Common Name Pembrolizumab
ChEMBL ID CHEMBL3137343
Indication hodgkin disease, melanoma, microsatellite instability, non-small-cell lung carcinoma, renal cell carcinoma, squamous cell carcinoma, squamous cell carcinoma of head and neck, transitional cell carcinoma, ureteral neoplasms, urethral neoplasms, urinary bladder neoplasms, urologic neoplasms
Drug Class Monoclonal antibodies: humanized, immunomodulating
Pembrolizumab
Get full access now